2.34
-0.05(-2.09%)
Currency In USD
Address
50 Hampshire Street
Cambridge, MA 02139
United States of America
Phone
617 315 2255
Website
Sector
Healthcare
Industry
Biotechnology
Employees
362
First IPO Date
June 03, 2021
| Name | Title | Pay | Year Born |
| Dr. Eric E. Hedrick M.D. | Chief Physician Executive | 575,100 | 1965 |
| Ms. Jamilu E. Rubin | Chief Financial Officer and Principal Financial & Accounting Officer | 626,804 | 1965 |
| Ms. Dina Ciarimboli J.D. | Gen. Counsel & Corporation Sec. | 628,628 | 1969 |
| Mr. Alexis A. Borisy A.M. | Founder & Executive Chairman of Board of Directors | 0 | 1972 |
| Mr. Robert Forrester LL.B. | Co-Founder & Advisor | 0 | 1964 |
| Dr. Peter B. Bach M.D., MAPP | Co-Founder & Advisor | 0 | 1965 |
| Sir Andrew Dillon CBE | Co-Founder & Advisor | 0 | N/A |
| Mr. Daniel Hoey | Chief of Technical Operations | 0 | 1967 |
| Ms. Rona Anhalt | Chief People Officer | 0 | 1965 |
| Dr. Carlos Garcia-Echeverria Ph.D. | Chief of RX Creation | 0 | 1965 |
| Dr. Christian Antoni M.D., Ph.D. | Chief Global Devel. Officer | 0 | 1962 |
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.